Lisa Astor

Natural killer–cell therapies are increasingly being explored as an alternative and promising approach to immunotherapy.

Nivolumab plus ipilimumab showed clinically meaningful overall survival results at 3 years among special populations of patients with metastatic non–small cell lung cancer.

Significant rates of homologous recombination deficiency somatic gene mutations were found in patients with uterine serous cancer, resulting in possible implications for future testing and treatment for the patient population, according to the results of a research study.

According to a phase 1b study, ibrutinib can modulate immune response and lead to some promising immune effects for patients with metastatic pancreatic ductal adenocarcinoma.

Recent successes have been observed for patients with locally advanced, unresectable non–small cell lung cancer regarding new treatment options.

An updated guideline and panel recommends treatment with sacituzumab govitecan for patients with HR-positive/HER2-negative metastatic breast cancer who are refractory to endocrine therapy.

Pixatimod and nivolumab showed benefits for patients with microsatellite-stable metastatic colorectal cancer.

Neoadjuvant chemotherapy with carboplatin has been shown to improve the pathologic complete response rate for patients with triple negative breast cancer.

In the NORA study, a 16% reduction in the risk of death was achieved with maintenance niraparib in patients with platinum-sensitive recurrent ovarian cancer.

In a single-institution phase 1 trial, patients with large B-cell lymphoma had high overall response rates with CD22-directed CAR T-cell therapy.

Presenters at the 2022 San Antonio Breast Cancer Symposium discussed how antibody-drug conjugates have been changing the treatment landscape for patients with breast cancer.

NRG-GI002 helps to provide further total neoadjuvant therapy outcome data from multi-institutional national clinical trials that can benchmark and be used for future locally advanced rectal cancer outcomes, according to Thomas J. George, MD, FACP.

Several studies with data released or presented in 2022 did not meet the threshold for significance or achieve their primary end points. Although such results are disappointing, takeaways from the trials can be used by the field as a whole to improve clinical trial design and achieve greater success in the future.

The generation in development offers reasons for excitement about improved outcomes for patients with breast cancer.

New clinical trial data have shown that patients with IHC 1+ or IHC 2+/ISH– disease, but no ERBB2 amplification, could still benefit from HER2 targeted therapies.

Neoadjuvant immunotherapy has begun to show benefit for the treatment of patients with rectal cancer as well as for those with colorectal cancer.

Improvement in progression-free and overall survival was shown with sacituzumab govitecan in the phase 3 TROPiCS-02 trial.

Findings from the HER2CLIMB clinical trial of tucatinib combined with trastuzumab and capecitabine verified the safety of the regimen in patients with HER2-positive metastatic breast cancer.

In data from a first-in-human study of a novel MPS1 inhibitor in patients with advanced solid tumors, clinical activity was observed.

In a phase 1 study, a peptide conjugated vaccine showed potent immunogenicity and was able to induce functional T-cell responses in almost all vaccinated patients with HPV16-positive premalignancies.

There was a potential antitumor signal observed with NGM120 in combination with chemotherapy, according to Andrew E. Hendifar, MD.

Tepotinib plus gefitinib led to improvements in progression-free survival and overall survival in patients with EGFR-mutant non–small cell lung cancer.

Updated data from the phase 3 CheckMate 9LA trial showed that the combination of nivolumab, ipilimumab, and 2 cycles of chemotherapy elicited survival benefit in patients with treatment-naïve metastatic non–small cell lung cancer.

In patients with non–small cell lung cancer who harbor an EGFR exon 20 insertion mutation, sunvozertinib demonstrated promising efficacy.

Tepotinib was able to provide clinically meaningful activity in patients with high MET amplification non–small cell lung cancer in the VISION study, according to Xiuning Le, MD, PhD.

The combination of ivuxolimab and utomilumab was well tolerated in patients with advanced solid tumors, according to a phase 1 study.

Following the success of immunotherapy-based therapy, investigators continue to explore new approaches for patients in a rapidly evolving field to continue to move the needle toward improved outcomes for patients with kidney cancer.

Two ambulatory infusion centers, Houston Methodist Baytown Hospital (Baytown) and Houston Methodist West Hospital (West), implemented the multidisciplinary program in 2020. The study continued through October 2021.

Many studies’ results have suggested that the use of ctDNA for monitoring responses to treatment could be a significant tool for clinical research as well as a predictive biomarker.